BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 21406517)

  • 1. Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.
    Hall SM; Davie N; Klein N; Haworth SG
    Eur Respir J; 2011 Oct; 38(4):851-60. PubMed ID: 21406517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosentan inhibits cigarette smoke-induced endothelin receptor expression in pulmonary arteries.
    Milara J; Gabarda E; Juan G; Ortiz JL; Guijarro R; Martorell M; Morcillo EJ; Cortijo J
    Eur Respir J; 2012 Apr; 39(4):927-38. PubMed ID: 21828025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to bosentan in children with pulmonary hypertension.
    Maiya S; Hislop AA; Flynn Y; Haworth SG
    Heart; 2006 May; 92(5):664-70. PubMed ID: 16216850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006.
    Haworth SG; Hislop AA
    Heart; 2009 Feb; 95(4):312-7. PubMed ID: 18952635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion?
    Brancaccio G; Toscano A; Bevilacqua M; Di Chiara L; Parisi F
    Pediatr Transplant; 2007 Feb; 11(1):110-2. PubMed ID: 17239133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
    McLaughlin VV
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling.
    Tofovic SP; Jones TJ; Bilan VP; Jackson EK; Petrusevska G
    J Cardiovasc Pharmacol; 2010 Nov; 56(5):475-83. PubMed ID: 20881615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Betamethasone attenuates oxidant stress in endothelial cells from fetal lambs with persistent pulmonary hypertension.
    Chandrasekar I; Eis A; Konduri GG
    Pediatr Res; 2008 Jan; 63(1):67-72. PubMed ID: 18043518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelin A receptor blockade improves regression of flow-induced pulmonary vasculopathy in piglets.
    Mercier O; Sage E; Izziki M; Humbert M; Dartevelle P; Eddahibi S; Fadel E
    J Thorac Cardiovasc Surg; 2010 Sep; 140(3):677-83. PubMed ID: 20723731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan.
    Beghetti M
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():16-24. PubMed ID: 16919006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.
    Hoeper MM; Faulenbach C; Golpon H; Winkler J; Welte T; Niedermeyer J
    Eur Respir J; 2004 Dec; 24(6):1007-10. PubMed ID: 15572546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful epoprostenol withdrawal in pulmonary arterial hypertension: case report and literature review.
    Demerouti EA; Manginas AN; Athanassopoulos GD; Karatasakis GT; Leontiadis ED; Pavlides GS
    Respir Care; 2013 Feb; 58(2):e1-5. PubMed ID: 22710078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evidence-based approach to the management of pulmonary arterial hypertension.
    Archer SL; Michelakis ED
    Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of pulmonary arterial hypertension.
    Humbert M; Sitbon O; Simonneau G
    N Engl J Med; 2004 Sep; 351(14):1425-36. PubMed ID: 15459304
    [No Abstract]   [Full Text] [Related]  

  • 17. Pulmonary hypertension in thoracic surgical patients.
    Ross AF; Ueda K
    Curr Opin Anaesthesiol; 2010 Feb; 23(1):25-33. PubMed ID: 20019603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin antagonism in pulmonary arterial hypertension.
    Lee SH; Channick RN
    Semin Respir Crit Care Med; 2005 Aug; 26(4):402-8. PubMed ID: 16121317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary arterial hypertension: combination therapy in the modern management era.
    Sitbon O
    Eur Respir Rev; 2010 Dec; 19(118):348-9. PubMed ID: 21119195
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.